Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. - Wikidata - wikimedia - TriplyDB

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

http://www.wikidata.org/entity/Q37679776

about

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives Advances and Challenges of Liposome Assisted Drug Delivery US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Clinical applications of pulmonary delivery of antibiotics Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights Inhaled antibiotics for lower airway infections.Rifabutin Is Active against Mycobacterium abscessus Complex.Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series.Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.Human infections due to nontuberculous mycobacteria: the infectious diseases and clinical microbiology specialists' point of view.Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature.Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-resistant Mycobacterium abscessus Lung Disease.Mycobacterium abscessus Complex - a Particular Challenge in the Setting of Lung Transplantation.Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis.Antibiotic treatment for nontuberculous mycobacterial lung disease.Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease.Treatment of Non-Tuberculous Mycobacterial Lung Disease.Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence.The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.A Breath of Fresh Air for Patients with Pulmonary Nontuberculous Mycobacterial Infection.Mixed Infection of Mycobacterium abscessus subsp. abscessus and Mycobacterium tuberculosis in the Lung.Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.[Nontuberculous mycobacterial pulmonary disease].Mycobacterium abscessus disease in lung transplant recipients: Diagnosis and management.Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward.Amikacin: Uses, Resistance, and Prospects for Inhibition.Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages.Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent Clinical aspects in patients with pulmonary infection caused by mycobacteria of the Mycobacterium abscessus complex, in the Brazilian Amazon : Shapeshifter of the Mycobacterial World

P2860

Q26747065-1A7375EB-0613-420B-96A3-98E56F5628FA Q26748674-241E3557-F9E0-4E61-961E-3C0DA70C4137 Q26749480-F6A9C485-31E5-499E-B668-79604236449D Q26773160-AFF961EA-C46E-4027-AEFB-CE6B45E40B6B Q26775974-8F9D012B-A938-4FDA-B83A-AB378FD2A72F Q26822988-ED1AA01E-BA12-4AC1-B1C0-2EA62EE4EC0A Q26996053-52CBD756-D4B7-4B64-B02A-E1467FF1670D Q28087593-974D1F63-63F2-46BA-895A-B931117AB579 Q33640488-F70E6F54-4D43-4B28-8AD0-8951DFE0B43A Q33726686-7A16DB2E-C667-4ED4-8867-4388C0BB0CDE Q33755342-D36BB0A5-CB0C-42D5-834D-0A0BB1E67574 Q35859886-A9D932F2-D109-4A64-A576-60D4CD32899A Q36099490-8A7F7347-56F2-4565-94C4-B1841CF2C869 Q36411357-57E003B4-E73D-4ADC-87A2-229BC6ABB42D Q36567746-D93771B2-A9C5-462F-8DCB-DF926893287D Q37613058-5010E598-A669-4417-85DB-E32D3A6EC529 Q38224821-97FAA374-8967-4F76-8572-1C0D7A7CCD4B Q38579967-CCA1975B-734E-4739-B7F8-429C622FA4E7 Q38581888-C4F5EB03-67F9-4975-8AC2-4097C82778C6 Q38630117-E387B959-F71F-4141-A0CB-738A1E4B7323 Q38663720-C8D94D1D-4E21-4914-8D89-370DCBDAA6D6 Q38687467-0CF47FF0-9216-4927-A419-228CA2E1D7BC Q38749090-EDD3626C-F3F1-4894-A1EE-2055BAF66206 Q38770072-C1C24357-CB9B-4471-A621-62B6228F3053 Q38988324-145E410A-61EC-4506-83F5-60300423CE59 Q39321216-9B82969C-525E-403D-82A1-C3557741A093 Q40093562-34D32F3E-D8C0-46C2-B112-23D7B5DBA055 Q40100000-F0261BDB-F160-4ADF-BF64-6EB04FD1ED62 Q40293783-148C0EF3-5E29-4F7E-89AC-A9ED18973AA8 Q40339339-D4586960-C405-4D5D-B4C1-E5CD2CDEA396 Q40504302-78076C39-83A8-49D5-803C-49A6E042CDD3 Q40818353-97048936-7EAF-4A35-9908-09D687F3563C Q47650898-66F41495-DF49-4860-B972-5186F66AF8F5 Q47960948-39732DBA-101D-4085-8645-1300C97B120A Q52744431-BD74A580-E3BD-4D4F-90A4-1FAD66D76605 Q55057435-057802D1-E0F6-4572-8736-A2E75D83A08F Q57191759-064826D8-0BA1-4E0D-B2E5-1F5209349AD9 Q57571911-5ACEB763-C6AA-4A7F-BB1D-6EA593CE68BE Q59132952-4ADB1B04-38AB-4869-B2EE-38FA8528EC4C

P2860

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

http://www.wikidata.org/entity/Q37679776

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@en

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@nl

type

label

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@en

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@nl

prefLabel

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@en

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@nl

P1433

Q37679776-D8B668BD-D41C-4F62-A60C-501C99B5A55F

P1476

Q37679776-EE116A9F-A26D-498E-97C8-2446E389EA32

P2093

Q37679776-1AF10A8E-EE73-40B0-98CF-98D1F4BAAD00

Q37679776-1F0B3264-807D-489F-BEA2-4C7A97E4E3FE

Q37679776-4F5A4A6B-C518-4188-9A80-BEB4F7383FD6

Q37679776-5646A4FA-B8B3-47A6-B0EB-8D6E64F4CAC8

Q37679776-602CD73C-EAEF-4C9D-BCE4-F63FB7968E3A

Q37679776-840B36D0-5618-42F4-8908-E837556DDD7C

Q37679776-912DACEE-4098-42AE-B762-6011B694828B

Q37679776-A001BD96-5290-44B0-9E66-434BFF948F2E

Q37679776-ACC828C3-489A-4721-A910-2D3CB26D9F8D

Q37679776-C1E89099-ADC7-431F-9A74-9F8493FE1268

P2860

Q37679776-02595022-E0A0-4CE1-9925-D173445807F0

Q37679776-0A5F0BBE-60D7-4C29-B5FA-88A7B940585C

Q37679776-23C5F648-F65E-45E1-AD8D-93242A1E5141

Q37679776-2E95CA8B-0614-427E-BD51-C89C60106DA6

Q37679776-3940D0FA-EAEB-4C06-839E-BF2082FDCFC1

Q37679776-757C15F0-5504-41F8-852D-C78363DCE215

Q37679776-942958AF-EA5E-41A7-A11A-46671F1FEBFC

Q37679776-AF014292-DA7B-40EF-8253-F956B3C99084

Q37679776-CF3958AB-5C0D-460D-ABF5-F91BE8637101

Q37679776-D6674B1A-97EF-499E-A694-10AABD54342A

P304

Q37679776-B641D99B-5D20-4C52-81CD-51DC5155F39A

P31

Q37679776-11621526-F68F-4AC5-9B87-B908D19CCF4A

P356

Q37679776-1201AB0A-52AC-4796-AC1F-A94B852971D6

P433

Q37679776-4E619D75-4081-4477-993A-AF49F2C39F0E

P478

Q37679776-78A57211-FCB5-48B0-937F-3145424C1E44

P50

Q37679776-62636A90-16F7-4F15-A459-59DB68E3AEAC

Q37679776-774DDD99-4400-424D-928E-C944CBE22E42

P577

Q37679776-CA035F9A-F37E-4195-A0FC-48C836446313

P698

Q37679776-EF139F3D-5292-4F0C-9C34-2A4C7DB01E58

P932

Q37679776-D3FC2065-B51D-4A14-B0E9-99AA8353A1E6

P356

ANNALSATS.201307-231OC

P1433

Proceedings of the American Thoracic Society

P1476

Inhaled amikacin for treatment ...... rculous mycobacterial disease.

@en

P2093

Adrian M Zelazny

http://www.w3.org/2001/XMLSchema#string

Carmen C Brewer

http://www.w3.org/2001/XMLSchema#string

Christopher K Zalewski

http://www.w3.org/2001/XMLSchema#string

D Rebecca Prevots

http://www.w3.org/2001/XMLSchema#string

Darshana Bhattacharyya

http://www.w3.org/2001/XMLSchema#string

Elizabeth P Sampaio

http://www.w3.org/2001/XMLSchema#string

In Kwon Park

http://www.w3.org/2001/XMLSchema#string

Kenneth N Olivier

http://www.w3.org/2001/XMLSchema#string

Les R Folio

http://www.w3.org/2001/XMLSchema#string

Pamela A Shaw

http://www.w3.org/2001/XMLSchema#string

P2860

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series.

Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.

Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance

Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii.

Diagnosis and treatment of infections due to Mycobacterium avium complex.

Nontuberculous mycobacterial lung disease.

Nontuberculous mycobacteria in patients with cystic fibrosis.

P304

30-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1513/ANNALSATS.201307-231OC

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Monika Fleshner

Jenifer R Siegelman

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24460437

http://www.w3.org/2001/XMLSchema#string

P932

3972984

http://www.w3.org/2001/XMLSchema#string